The intrathecal (i.t.) administration of
glutamate (10-100 nmol) caused dose-related
hyperalgesia (mean ED50 of 35 nmol) when assessed in the thermal behaviour model of nociception, the hot-plate test maintained at 50 degrees C. The i.p., i.t. or intracerebroventricular (i.c.v.) injection of the
nitric oxide synthase inhibitors, L-
NOARG and
L-NAME, did not induce any detectable effect per se, but instead, produced dose-related inhibition of
glutamate-induced
hyperalgesia. D-NAME, the inactive enantiomer of
L-NAME, had no effect. The i.c.v. or i.t. administration of
L-NIO caused graded attenuation of
glutamate-induced
hyperalgesia.
L-arginine (3.4 mmol kg(-1), i.p.), but not D-
arginine (3.4 mmol kg(-1), i.p.) significantly potentiated
glutamate (10 nmol)-induced
hyperalgesia, an action that was prevented by L-
NOARG (137 nmol kg(-1)). The co-injection of S-nitroso-N-acetyl-D,L-
penicillamine (SNAP) (0.22 micromol) or
8-bromo-cGMP (22.5 nmol) with
glutamate (10 nmol), via either i.t. or i.c.v. routes, also significantly enhanced
glutamate-induced
hyperalgesia. The
guanylate cyclase inhibitors
LY 83583 (0.1-1.0 nmol) or ODQ (30-300 pmol) co-administered with
glutamate, dose-dependently antagonised the
glutamate-induced
hyperalgesia. Collectively, these results demonstrate that the i.t. injection of
glutamate into the spinal cord of mice produces dose-related
hyperalgesia an effect that was largely mediated by the
L-arginine-
nitric oxide-cGMP pathway from both spinal and supraspinal sites.